Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Barbiturate with hypnotic and sedative properties.
It has been used in the treatment of insomnia, epileptic seizures and as a preanesthetic medication.
Its use has been replaced by other drugs with less risk of abuse/dependence, overdose and withdrawal syndrome (Suddock 2020).
Oral or parenteral administration.
At the date of the last update, there was no available published data on its excretion in breast milk.
Its pharmacokinetic data (low molecular weight, low protein binding and prolonged elimination) make it likely to pass into breast milk in an amount that could be significant.
Product marketed in very few countries.
Until more published data on this drug is known in relation to breastfeeding, known safer alternatives may be preferable, especially during the neonatal period and in the event of prematurity